Page 4 - Patrick Gaynes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements - 60 Degrees (NASDAQ:SXTP), 60 Degrees (NASDAQ:SXTPW)

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in

United statesSheilaa burkePatrick gaynesGeoff dowTafenoquine arakodaDegrees pharmaceuticals incWalter reed army institute of researchBp australia pty ltdUnited states department of defenseDrug administrationDegrees pharmaceuticalsKnight therapeutics incExchange commissionCenters for diseaseAustralia pty ltdWalter reed army institute

60 Degrees Pharmaceuticals (SXTP) Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

60 Degrees Pharmaceuticals (SXTP) Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPatrick gaynesTafenoquine arakodaGeoff dowSheilaa burkeCenters for diseaseDegrees pharmaceuticals incSixty degrees pharmaceuticalsDegrees pharmaceuticalsWalter reed army institute of researchBp australia pty ltdDrug administrationKnight therapeutics incExchange commissionUnited states department of defenseAustralia pty ltd

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND.

United statesGeoff dowPatrick gaynesSheilaa burkeTafenoquine arakodaWalter reed army institute of researchDrug administrationDegrees pharmaceuticalsExchange commissionDegrees pharmaceuticals incKnight therapeutics incBp australia pty ltdCenters for diseaseUnited states department of defenseAustralia pty ltdWalter reed army institute

Pasithea Therapeutics to Participate in H C Wainwright

Attendees may request 1 x 1 meeting with management at meetings@hcwco.com PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) .

New yorkUnited statesPatrick gaynesWhile the companyPasithea therapeutics corpCorporate communicationsCompany contactExchange commissionAnnual global investment conferenceNew york cityAmyotrophic lateral sclerosisMultiple sclerosisNasdaq kttaHc wainwrightInvestor conferencePasithea therapeutics

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode.

District of columbiaUnited statesSheilaa burkeGeoffrey dowPatrick gaynesTafenoquine arakodaKnight therapeutics incDegrees pharmaceuticalsDegrees pharmaceuticals incCenters for diseaseGlobenewswire incExchange commissionNational institute of allergyUnited states department of defenseNational institutes of healthWalter reed army institute of research